1、Breaking Through the Bottleneck of Traditional Screening | Customized In Vitro High-Throughput Panels Based on Cancer Types to Accelerate the Preclinical Translation of Antitumor Drugs

• Industry Pain Point：Traditional single-cell line screening models fail to simulate tumor heterogeneity and the impact of the microenvironment, leading to a disconnect between in vitro and in vivo drug efficacy and low clinical translation rates.
• Value Proposition: Significantly improve the accuracy of drug sensitivity prediction and shorten the R&D cycle by more than 30% through multi-dimensional cancer type-customized panels (covering more than 15 cancer types).

2、Service Overview

In vitro high-throughput drug candidate screening is a core step in the preclinical R&D of antitumor drugs. The industry currently faces two major challenges:

• Model Limitations: Single cell lines cannot reflect tumor heterogeneity and organ-specific microenvironments (e.g., significant differences in drug efficacy between orthotopic and subcutaneous models of lung cancer).
• Low Translation Rate: Only 20% of in vitro positive compounds maintain activity in in vivo validation.
• 3.Our Solutions
• Construct multi-cell line combined screening panels based on specific cancer types (e.g., 81 lung cancer strains, 42 colorectal cancer strains), integrate 3D organoids and functional assays (migration/invasion), and realize a leap from “single-target” to “multi-dimensional” screening.
• Core Objective: Enhance clinical relevance.

3、Our Services

1. Cancer Type-Customized Panels

Special Panel: Chinese Primary Tumor Cell Bank (more than 100 types), supporting rare cancer types such as thyroid cancer and gallbladder cancer.

2. Functional Detection Modules
   • Migration/Invasion Assay: Quantitative detection of drug inhibition on tumor metastasis via Transwell (15-20 working days).
   • 3D Organoid Drug Sensitivity: Simulate the in vivomicroenvironment to evaluate the effect of drugs on cancer stem cells.
   • Drug-Resistant Strain Combined Screening: Provide drug-resistant strains such as DDP, ADM and PTX to verify the potential of drugs to overcome drug resistance.

3. Value-Added Special Services

• Fluorescent Tracer Cell Lines: Real-time monitoring of drug inhibition on tumor growth/metastasis (e.g., HepG2-luc liver cancer orthotopic model).
• Pathway Activity Analysis: Verify target dependence based on CRISPR-Cas9 tool cells.

4、Technical Platforms and Advantages

1. Technical Platforms

• Cell Bank Platform: More than 1000 commercial cell banks + more than 100 Chinese primary tumor cell banks.
• High-Throughput Automated System: Microplate reader + high-content imaging, processing more than 1000 samples per day.
• In Vitro Drug Sensitivity Platform: Primary tumor cell culture and rapid drug sensitivity testing.

2. Differentiated Advantages

• Uniqueness: Simultaneous support for combined screening of primary cells and organoids.
• Accuracy: The coincidence rate of clinical response prediction by EGFR-mutant cell lines in the lung cancer panel is over 85%.
• Innovation: Independent development of more than 300 fluorescent tracer/drug-resistant/gene-edited cell lines.

5、Service Process

1. Needs Communication (1 working day): Customize panel solutions (e.g., “Lung Cancer Targeted Drug Panel: 10 EGFR-mutant cell lines + 3D organoids”)
2. Experiment Execution:

• Cell culture and drug treatment (provide a standardized culture condition report).
• Real-time data sharing (e.g., original data of cell proliferation curves).

3. Data Delivery (10-15 working days):

• GLP-aligned reports (including dose-response curves, IC50 calculation, statistical analysis).
• Optional expedited service (30% reduction in cycle time).

6、Quality Control and Compliance

• Cell Quality Control: STR authentication (human-derived cells), mycoplasma testing (ISO 17025 standard).
• Data Compliance: Electronic traceability of experimental records, in compliance with 21 CFR Part 11.
• Report Standards: Provision of original data + analytical methodology + QC control charts.

7、Case Studies

Case 1: Screening with Lung Cancer Targeted Drug Panel

• Customer Demand: Evaluate EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) resistance-breaking compounds.
• Solution: 15 lung cancer cell lines (including H1975-T790M drug-resistant strains) + Transwell migration assay.
• Result: The Tumor Growth Inhibition (TGI) of lead compound A1 in the H358 CDX (Cell-Derived Xenograft) model reached 68%.

Case 2: Screening with Liver Cancer Combination Therapy Panel

• Solution: 38 liver cancer cell lines + organoid models.
• Result: Discovery of a synergistic effect between lenvatinib and PD-1 inhibitor.

For more cases: [link to the company case library]

8、Cooperation Advantages

• Customization: Customize panels according to drug mechanisms of action (e.g., target pathways), supporting the full cycle from lead compound optimization to IND (Investigational New Drug) application.
• Efficiency: Standard testing cycle is 30% faster than the industry average, and expedited projects can be launched within 72 hours.
• End-to-End Support: Can be connected with in vivo PDX (Patient-Derived Xenograft) model validation, providing a one-stop solution for translational research.

9、FAQ

Q1: Is customization of panels for rare cancer types supported?

A: Relying on the Chinese Primary Tumor Cell Bank (more than 100 types), panels for thyroid cancer, gallbladder cancer and other rare cancer types can be constructed.

Q2: Can the data delivery cycle be shortened?

A: Expedited service is supported, and cell proliferation testing can be delivered in as fast as 10 working days (30% additional fee required).

10、Laboratory Highlights

• Processing over 1000 samples per day
• Simulating the tumor microenvironment
• Ensuring contamination-free operation

View More

11、Contact Us

• Technical Consultation: 3691125803@qq.com| +86 18802035152
• Free Customized Solution: [online demand submission form]
• Resource Download:

• Guidelines for the Construction of Tumor Drug Screening Panels[Download]
• Case Collection Translational Strategies from In Vitro to In Vivo[Download]

Get your exclusive solution now → [Request a Free Consultation]